N,N-dimethyl-8-[(4-methylpiperidin-1-yl)carbonyl]-2-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indole-5-sulfonamide | 910798-97-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N,N-dimethyl-8-[(4-methylpiperidin-1-yl)carbonyl]-2-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indole-5-sulfonamide
• 英文别名: N,N-dimethyl-8-(4-methylpiperidine-1-carbonyl)-2-(oxan-4-yl)-3,4-dihydro-1H-pyrido[4,3-b]indole-5-sulfonamide
• CAS: 910798-97-9
• 化学式: C₂₅H₃₆N₄O₄S
• 分子量: 488.651
• InChiKey: IOBGWHNZXXNBCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  83.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚-8-羧酸 在 三乙酰氧基硼氢化钠 、 sodium hydride 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 、 sodium hydroxide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 N,N-dimethyl-8-[(4-methylpiperidin-1-yl)carbonyl]-2-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indole-5-sulfonamide
  参考文献：
  名称：

  γ-Carbolines: A novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration

  摘要：

  An oral, peripherally restricted CB1/CB2 agonist could provide an interesting approach to treat chronic pain by harnessing the analgesic properties of cannabinoids but without the well-known central side effects. gamma-Carbolines are a novel class of potent mixed CB1/CB2 agonists characterized by attractive physicochemical properties including high aqueous solubility. Optimization of the series has led to the discovery of 29, which has oral activity in a rat inflammatory pain model and limited brain exposure at analgesic doses, consistent with a lower risk of CNS-mediated tolerability issues. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.12.124

文献信息

• Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands
  申请人：Cheng Yun-Xing

  公开号：US20100113502A1

  公开（公告）日：2010-05-06

  Compounds of formulae I, or pharmaceutically acceptable salts thereof: wherein R 1 , R 2 and R 3 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  化合物I的公式，或其药学上可接受的盐：其中R1、R2和R3如规范中所定义，以及包括这些化合物的盐和药物组合物已被制备。它们在治疗中很有用，特别是在疼痛管理方面。
• NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1' RECEPTOR LIGANDS
  申请人：AstraZeneca AB

  公开号：EP1863810A1

  公开（公告）日：2007-12-12
• [EN] NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1' RECEPTOR LIGANDS<br/>[FR] NOUVEAUX DERIVES DE TETRAHYDRO-1H-PYRIDO [4,3-B]INDOLE UTILISES COMME LIGANDS DU RECEPTEUR CB1'
  申请人：ASTRAZENECA AB

  公开号：WO2006101434A1

  公开（公告）日：2006-09-28

  [EN] Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein R¹, R² and R³ are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
  [FR] L'invention concerne des composés de formule (I), ou des sels pharmaceutiquement acceptables desdits composés, dans laquelle R¹, R² et R³ sont tels que définis dans le mémorandum descriptif. Elle concerne également des sels et des compositions pharmaceutiques comprenant les composés, lesquels sont utiles en thérapie, en particulier pour l'apaisement de la douleur.
• γ-Carbolines: A novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration
  作者：Yun-Xing Cheng、Mehrnaz Pourashraf、Xuehong Luo、Sanjay Srivastava、Christopher Walpole、Dominic Salois、Stephane St-Onge、Kemal Payza、Etienne Lessard、Xiao Hong Yu、Mirosław J. Tomaszewski

  DOI：10.1016/j.bmcl.2011.12.124

  日期：2012.2

  An oral, peripherally restricted CB1/CB2 agonist could provide an interesting approach to treat chronic pain by harnessing the analgesic properties of cannabinoids but without the well-known central side effects. gamma-Carbolines are a novel class of potent mixed CB1/CB2 agonists characterized by attractive physicochemical properties including high aqueous solubility. Optimization of the series has led to the discovery of 29, which has oral activity in a rat inflammatory pain model and limited brain exposure at analgesic doses, consistent with a lower risk of CNS-mediated tolerability issues. (C) 2012 Published by Elsevier Ltd.